CompletedPhase 2

Efficacy of SMOF Lipid in the Management of Acute Poisoning With Clozapine

Egypt40 participantsStarted 2022-01-01

Plain-language summary

The goal of the current study was to evaluate whether SMOF lipid administration could be used as an adjuvant therapy to treat acute, moderate-to-severe clozapine poisoning.

Who can participate

Age range18 Years – 66 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: The patients were enrolled in the study in accordance with the following: Gender and age: adult symptomatic males and females. Patients were admitted within 12 hours of exposure to the poison. Patients received no prior treatment before admission. Patients with moderate-to-severe carbamazepine poisoning according to the Poisoning Severity Score (PSS) Patients classified as high-risk (HR) with anti-depressant overdose risk assessment (ADORA) criteria. Exclusion Criteria: Patients were excluded if they had any of the following conditions: pregnant and lactating women. Patients with major medical conditions (e.g. diabetes mellitus), cardiovascular disease, renal, or hepatic failure). Patients suffering from hyperlipidemia. Malignancy. Co-ingestion.

What they're measuring

Improvement in Conscious Levels Measured by Glasgow Coma Scale (GCS)

Timeframe: participants were monitored within 24 hours from admission to the hospital

Assessment of Intubation Requirement Using APACHE

Timeframe: participants were assessed within 24 hours from admission to the hospital

Length of Intensive Care Unit (ICU) Stay

Timeframe: up to one month

length of hospital stay

Timeframe: up to one month

Trial details

NCT IDNCT06413589

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-01

View on ClinicalTrials.gov More Acute Poisoning trials